B
Bull
Bull · 25%LUCD
$2.49
Scenario price
$0.991
+0.007 (+0.75%)At close
Loading chart…
- High
- 1.000
- Open
- 0.985
- VWAP
- 0.99
- Vol
- 426.79K
- Mkt Cap
- 45.55M
- Low
- 0.972
- Amount
- 421.57K
- EV/EBITDA, TTM
- 0.63
Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc.
AI analysis of Lucid Diagnostics Inc (LUCD)
buyLucid Diagnostics Inc (LUCD) appears to be a good buy right now, given its recent price of $0.99, which is significantly lower than the analyst price target of $9.50. Additionally, the stock has shown a positive momentum with a 5-day change of +2.81% and a 20-day change of +13.74%. The main risk is its high net loss, with a net income of -14,715,000 USD reported in Q2 2026, which indicates ongoing financial challenges that could affect future performance.
Valuation Metrics
The current forward P/E ratio for Lucid Diagnostics Inc (LUCD) is 0.00, compared to its 5-year average forward P/E of -2.09.
Alphio AI Price Scenarios for LUCD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding LUCD
Events Timeline
News
9.508-14PRnewswirePAVmed Provides Business Update and Q2 Financial Results
9.508-13PRnewswireLucid Diagnostics Reports Q2 2026 Financial Results and Business Update
8.508-05PRnewswireConcert Policy Recognizes EsoGuard® as Only Esophageal Precancer Test
1.008-04PRnewswireLucid Diagnostics to Participate in Upcoming Investor Conferences
4.508-03CNBCMarket Trends and Corporate Strategy Overview
LUCD FAQ — answered by Alphio AI
Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Lucid Diagnostics Inc (LUCD) appears to be a good buy right now, given its recent price of $0.99, which is significantly lower than the analyst price target of $9.50. Additionally, the stock has shown a positive momentum with a 5-day change of +2.81% and a 20-day change of +13.74%. The main risk is its high net loss, with a net income of -14,715,000 USD reported in Q2 2026, which indicates ongoing financial challenges that could affect future performance.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.